Evaluation of T- and NK-cell-targeted therapies: is there a role for rituximab prophylaxis?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 19293254.
- Also identified by DOI 10.1158/1078-0432.CCR-08-2905 and PMC identifier 5792055.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Splizimomab, an antibody that targets CD2, was studied in the treatment of T and natural killer cell lymphoma and was found to be associated with Epstein-Barr virus lymphoproliferative disease. B cell depletion may provide a platform for further evaluation of this and other promising antibody approaches that result in T cell depletion.
Medical subject headings
- Antibodies, Monoclonal
- Antineoplastic Agents
- Epstein-Barr Virus Infections
- Lymphoproliferative Disorders